TR2023000874A2 - COMPOSITION DEVELOPED FOR USE IN THE DRUG TREATMENT OF CHRONIC RENAL FAILURE OCCURS WITH AGE. - Google Patents
COMPOSITION DEVELOPED FOR USE IN THE DRUG TREATMENT OF CHRONIC RENAL FAILURE OCCURS WITH AGE.Info
- Publication number
- TR2023000874A2 TR2023000874A2 TR2023/000874 TR2023000874A2 TR 2023000874 A2 TR2023000874 A2 TR 2023000874A2 TR 2023/000874 TR2023/000874 TR 2023/000874 TR 2023000874 A2 TR2023000874 A2 TR 2023000874A2
- Authority
- TR
- Turkey
- Prior art keywords
- age
- renal failure
- treatment
- failure
- chronic renal
- Prior art date
Links
- 208000020832 chronic kidney disease Diseases 0.000 title claims abstract description 34
- 238000011282 treatment Methods 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 208000022831 chronic renal failure syndrome Diseases 0.000 title claims abstract description 27
- 229940079593 drug Drugs 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims abstract description 19
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960000711 alprostadil Drugs 0.000 claims abstract description 15
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960005192 methoxamine Drugs 0.000 claims abstract description 14
- WZGBZLHGOVJDET-UHFFFAOYSA-N nizofenone Chemical compound CCN(CC)CC1=NC=CN1C1=CC=C([N+]([O-])=O)C=C1C(=O)C1=CC=CC=C1Cl WZGBZLHGOVJDET-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960000823 nizofenone Drugs 0.000 claims abstract description 7
- 238000000502 dialysis Methods 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 9
- 208000001647 Renal Insufficiency Diseases 0.000 description 8
- 238000001631 haemodialysis Methods 0.000 description 8
- 230000000322 hemodialysis Effects 0.000 description 8
- 201000006370 kidney failure Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 208000009304 Acute Kidney Injury Diseases 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 4
- 208000033626 Renal failure acute Diseases 0.000 description 4
- 201000011040 acute kidney failure Diseases 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 239000003708 ampul Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 208000028208 end stage renal disease Diseases 0.000 description 3
- 201000000523 end stage renal failure Diseases 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- -1 vial Substances 0.000 description 3
- 208000007122 AIDS-Associated Nephropathy Diseases 0.000 description 2
- 206010070737 HIV associated nephropathy Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000003896 Myeloperoxidases Human genes 0.000 description 2
- 108090000235 Myeloperoxidases Proteins 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 208000012998 acute renal failure Diseases 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012959 renal replacement therapy Methods 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- TWUSDDMONZULSC-HZMBPMFUSA-N (1r,2s)-2-(tert-butylamino)-1-(2,5-dimethoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(OC)C([C@@H](O)[C@H](C)NC(C)(C)C)=C1 TWUSDDMONZULSC-HZMBPMFUSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 1
- LATVFYDIBMDBSY-UHFFFAOYSA-N 2,5-dimethoxyamphetamine Chemical compound COC1=CC=C(OC)C(CC(C)N)=C1 LATVFYDIBMDBSY-UHFFFAOYSA-N 0.000 description 1
- 101150114038 APOL1 gene Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102100030762 Apolipoprotein L1 Human genes 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018001 Gastrointestinal perforation Diseases 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101100323521 Homo sapiens APOL1 gene Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010022680 Intestinal ischaemia Diseases 0.000 description 1
- 206010061249 Intra-abdominal haemorrhage Diseases 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000004535 Mesenteric Ischemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 101150109862 WNT-5A gene Proteins 0.000 description 1
- 102000043366 Wnt-5a Human genes 0.000 description 1
- 108700020483 Wnt-5a Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000533 adrenergic alpha-1 receptor agonist Substances 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229950009770 butaxamine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000003017 ductus arteriosus Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000011457 non-pharmacological treatment Methods 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 230000003823 potassium efflux Effects 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000002693 spinal anesthesia Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Abstract
Bu buluş; Yaş ile beraber ortaya çıkan KRONİK BÖBREK yetmezliğinin ilaç tedavisinde kullanılmak üzere geliştirilmiş bir kompozisyon ile ilgili olup; Methoxamine (1), Alprostadil (2) ve Nizofenone (3) kısımlarını içermektedir.This invention; It is about a composition developed for use in the drug treatment of CHRONIC RENAL FAILURE that occurs with age; It contains Methoxamine (1), Alprostadil (2) and Nizofenone (3).
Description
TARIFNAME YAS ILE BERABER ORTAYA ÇIKAN KRONIK BÖBREK YETERSIZLIGININ ILAÇ TEDAVISINDE KULLANILMAK ÜZERE GELISTIRILMIS BIR KOMPOZISYON Bu bulus: Yas ile beraber ortaya çikan KRONIK BÖBREK yetmezliginin ilaç tedavisinde kullanilmak üzere gelistirilmis bir kompozisyon ile ilgili olup; Methoxamine, Alprostadil ve Nizofenone kisimlarindan olusmaktadir. Son dönem böbrek hastaligi olarak da bilinen böbrek yetmezligi, böbreklerin artik kandaki atik ürünleri yeterince filtreleyemedigi ve normal seviyelerin %15 'inden daha az islev gördügü tibbi bir durumdur. Böbrek yetmezligi, hizla gelisen ve çözülebilen akut böbrek yetmezligi olarak siniflandirilir ve yavas gelisen ve genellikle geri döndürülemez olabilen kronik böbrek yetmezligi. Akut böbrek yetmezliginin nedenleri arasinda düsük kan basinci, idrar yollarinin tikanmasi, bazi ilaçlar, kas yikimi ve hemolitik üremik sendrom yer alir. Teknigin Bilinen Durumu Kronik böbrek yetmezliginin nedenleri arasinda diyabet, yüksek tansiyon, nefrotik sendrom ve polikistik böbrek hastaligi yer alir. Akut yetmezligin teshisi siklikla azalmis idrar üretimi veya artmis serum kreatinin gibi faktörlerin bir kombinasyonuna dayanir. APOLl geni, Afrika kökenli bireylerde diyabetik olmayan böbrek yetmezligi spektrumu için majör bir genetik risk lokusu olarak önerilmistir, bunlar arasinda HIV ile iliskili nefropati (HIVAN), fokal segmental glomerülosklerozun primer monojenik olmayan formlari ve hipertansiyona bagli kronik böbrek hastaligi yer alir. APOLl'deki iki Bati Afrika varyantinin, Afrikali Amerikalilar ve Hispanik Amerikalilarda son dönem böbrek hastaligi ile iliskili oldugu gösterilmistir. Akut yetmezligin tedavisi altta yatan nedene baglidir. Kronik yetmezligin tedavisi hemodiyaliz, periton diyalizi veya böbrek naklini içerebilir. Kronik yetmezligin tedavisi hemodiyaliz, periton diyalizi veya böbrek nakli içerebilir. Hemodiyaliz, kani vücut disinda filtrelemek için bir makine kullanir. Periton diyalizinde karin bosluguna spesifik sivi yerlestirilir ve ardindan bosaltilir, bu islem günde birkaç kez tekrarlanir. Böbrek nakli cerrahi olarak baska birinden alinan bir böbregi yerlestirmeyi ve ardindan reddi önlemek için bagisiklik sistemini baskilayici ilaç almayi içerir. Kronik hastaliga karsi önerilen diger önlemler arasinda aktif kalma ve belirli diyet degisiklikleri yer alir. Depresyon, böbrek yetmezligi olan hastalarda da yaygindir ve böbrek fonksiyonlarinda azalma, hastaneye yatis ve ölüm riskinin artmasi gibi kötü sonuçlarla iliskilidir. Ayakta hemodiyaliz alan böbrek yetmezligi hastalarinda yakin zamanda PCORI tarafindan finanse edilen bir çalisma, depresyon için farmakoloj ik ve farmakoloj ik olmayan tedaviler arasinda benzer etkinlik bulmustur. Kronik böbrek yetmezligi, kisinin GFR'si veya glomerüler filtrasyon hizi kullanilarak hesaplanan bes asamada ölçülür. Evre 1 KBH, birkaç belirgin semptomla hafif derecede azalmis böbrek fonksiyonudur. Asama 2 ve 3, böbrek islev bozukluklarini yavaslatmak ve tedavi etmek için tibbi saglayicilarindan artan düzeyde destekleyici bakima ihtiyaç duyar. Evre 4 ve 5 böbrek yetmezligi olan kisilerin hayatta kalabilmeleri için genellikle aktif tedaviye hazirlanmalari gerekir. Evre 5 KBH ciddi bir hastalik olarak kabul edilir ve mümkün oldugunda bir çesit renal replasman tedavisi ( diyaliz ) veya böbrek nakli gerektirir. Hemodiyalize giren son dönem böbrek yetmezligi hastalarinda spontan intraabdominal kanama riski genel popülasyona (%21,2) ve tikayici olmayan mezenterik iskemiye (%18,1) göre daha yüksektir. Bu arada, periton diyalizi geçirenlerde peritonit ve gastrointestinal perforasyon gelisme sansi daha yüksektir . Bununla birlikte, akut pankreatit orani genel popülasyondan farkli degildir. Akut böbrek hasarinin tedavisi nedene baglidir. Kronik böbrek yetmezliginin tedavisi renal replasman tedavisini içerebilir: hemodiyaliz, periton diyalizi veya böbrek nakli. Kronik böbrek yetersizligi, her yil yeni kronik böbrek yetmezligi yaklasik her 10.000 kisiden 3'ü ile 1.000 kisiden 1'inde gelisir. Akut böbrek yetersizligi genellikle geri döndürülebilirken, kronik yetersizlik genellikle geri döndürülemez. Bulusun Açiklamasi Amerika Birlesik Devletleri'nde böbrek naklinde akut basarisizlik, yilda yaklasik 1000 kisiden 3'ünü etkiler. Kronik böbrek yetersizligi, her yil yeni kronik böbrek yetmezligi tespit edilen Çin'de her yil hemodiyaliz veya periton diyalizi alan 395.121 kisi var. Kronik böbrek hastaligi olan Çinli nüfusun yüzdesi % 10,8'dir. tüm Medicare bütçesinin yüzde altisini olusturuyordu. Böbrek hastaligi dokuzuncu önde gelen ölüm nedenidir ve ABD, sanayilesmis dünyada diyaliz bakimi için en yüksek ölüm oranlarindan birine sahiptir. Ingiltere'de, diyaliz hizmeti NHS England tarafindan yürütülür. Her yil yaklasik 23.000 hasta hizmeti kullaniyor. Kronik Böbrek yetmezliginde böbrek transplantasyonu veya hemodiyaliz disinda seçenek olmadigi kabul edilmektedir. Yasa bagli gelisen böbrek yetmezliginin ilaç tedavisi bilinmemektedir. Oysa bizim gelistirdigimiz tedavi protokolü yasa bagli gelisen 3. veya 4. Evre böbrek yetmezligi bulunan yasli hastalarin böbrek fonksiyonlarinin düzelebilecegine ve diyalize muhtaç kalmayabileceklerine inaniyoruz. Gelistirdigimiz tedavi protokolü ile ilaç tedavisi özellikle erken evre Kronik Böbrek yetmezliginin iyilesmesi mümkün olacaktir. Özellikle yeni Kronik Böbrek yetmezligi tanisi konmus hastalar bizim gelistirdigimiz tedavi protokolü ile tedavi edilirlerse hasta tam sifa bulabilecektir. Tedavi protokolünün, uygulanmasi sinirli bir süreyi kapsamaktadir. Hasta hayati boyunca ilaç kullanmaktan kuitulacaktir. Kronik Böbrek yetmezligi olan hastalarin çalisma hayatina dahil olmasi ile çalisma hayatindaki is gücü kaybi önlenebilecek, sigorta tedavi maliyetleri çok azalacaktir. Aile ve ülke ekonomisine verdigi kayiplar önlenebilecektir. Bizim gelistirdigimiz yeni tedavi protokolü ile Kronik Böbrek yetmezliginin sagaltimi öz konusu olacaktir. Hastaligin ilerlemesi durdurularak hastalarin Kronik Böbrek yetmezliginden kurtulmasi mümkündür. Hastalarin yasamlari boyunca ilaç kullanmalarinin önüne geçilecektir. Bu nedenle sürekli ilaç kullanmanin getirdigi ilaçlara bagli yan etkiler önlenebilecektir. Hastalarin çalisma hayatlarindaki yasam kaliteleri yasina uygun olacak ve hastalarin çalisma hayatindaki mesai kayiplarina bagli ekonomik kayip bertaraf edilecektir. Kronik Böbrek yetmezligi nedeniyle çalisma hayatinda verimliligi düsen ve günlük yasam kaliteleri ve özgürlükleri sinirlanan milyonlarca hasta insan vardir. Gerek tedavi-ilaç masraflari ve gerekse günlük diyete uygun yasamak zorunda kalma stresi psikolojik yük olmaya devam etmektedir. Kronik Böbrek yetmezligi nedeniyle hastalarin saglik giderleri azaltilarak ülke ekonomilerine büyük katki saglayabiliriz. Yas ile beraber ortaya çikan KRONIK BÖBREK yetmezliginde önerdigimiz kompozisyon: Methoxamine (l), Alprostadil (2) ve Nizofenone (3) kisimlarindan olusmaktadir. Bizim önerdigimiz Yas ile beraber ortaya çikan KRONIK BÖBREK yetmezliginin ilaç tedavisinde kompozisyon kullanim süresi hastaligin evresine göre 1 - 6 ay süre verilebilir. 1. Metoksamin Metoksamin bir (11 - adrenerjik reseptör agonistidir. Hipotansiyonu tedavi etmek için kullanilan bir alfa adrenerj ik agonisttir. Yapi olarak butaksamine ve 2,5- DMA'ya benzer. Metoksamin, saf bir alfa-l adrenerj ik reseptör agonisti olarak hareket ederek periferik vazokonstriksiyon yoluyla etki eder ve sonuç olarak sistemik kan basincini (hem sistolik hem de diyastolik) arttirir. Uzun süreli periferik vazokonstriksiyona neden olan bir alfa-adrenerj ik agonist. Merkezi sinir sistemi üzerinde herhangi bir dogrudan etkisi varsa da çok azdir. Metoksamin, hem sistolik hem de diyastolik kan basincini artiran güçlü bir sempatomimetik amindir. Metoksamin, spinal anestezi ile olusan akut hipotansif durumun önlenmesi ve tedavisi için endikedir. Ayrica kanamaya bagli hipotansiyonun, ilaçlara verilen tepkilerin, cerrahi komplikasyonlarin ve travma veya tümöre bagli beyin hasarina bagli sokun yardimci tedavisi olarak da endikedir. Metoksamin, her iki al-adrenerj ik reseptöre etki eder, ancak ß-adrenerj ik reseptörler üzerinde hiçbir etkisi yok gibi görünmektedir. Kalbin pompalama eyleminin gücünü artirarak ve periferik kan damarlarini daraltarak etki eder. 2. Alprostadil Prostaglandin El (PGEl) olarak da bilinen Alprostadil, güçlü bir vazodilatör ajandir. Alprostadil'in vazodilatasyon, endotel hücrelerini koruma ve nötrofil ve trombositlerin aktivasyonunu ve agregasyonunu inhibe etme gibi çok sayida etkisi vardir. Klinik arastirmalar, alprostadilin iskemi reperfüzyon hasari, kontrast nefropati ve diyabetik nefropati vb. tedavisinde miyeloperoksidaz (MPO), TNF-(x ve IL-6 gibi inflamatuar faktörlerin ekspresyonunu azaltabildigini göstermistir. Ayrica, PGEl miyokardiyal mikrosirkülasyonu iyilestirdi ve miyokardiyal hücrelerin apoptozunu hafifletti. Alprostadil olarak da bilinen prostaglandin El ( PGEl ), ilaç olarak kullanilan dogal olarak olusan bir prostaglandindir. Prostaglandin El, vazodilatör ilaç ailesindendir. Düz kaslari gevseterek kan damarlarini açarak çalisir. Dogustan kalp defekti olan bebeklerde duktus arteriozus cerrahisi yapilabilene kadar açmak için damar içine yavas enj eksiyonla kullanilir. Prostaglandin El, koroner arter hastaligi ve/veya genetik bir bozuklugu olmayan saglikli insanlarda dihomo-y-linolenik asitten (bir omega-6 yag asidi ) gerektigi gibi biyosentezlenir. Alprostadil, LPS (lipopolisakkarit) ile uyarilan H9c2 hücrelerinin hücre canliligini arttirdi, LDH (laktat dehidraz) ve troponin üretimini azaltti ve IL-lß, IL-6, IL-l7 ve TNF-a salgisini azaltti. Ayrica alprostadil, LPS ile tedavi edilen H9c2 hücrelerinde Wnt5a, JNK ve NF-KB'nin mRNA ekspresyonunu ve Wnt5 a, NF-KB ekspresyonunu ve p-JN K/JN K oranini azaltti. 3. Nizofenon Nizofenon, serebral anoksiyi (beyne oksijen beslemesinin kesilmesi) takiben nöronlari ölümden koruyan nöroprotektif bir ilaçtir. Bu nedenle inme gibi akut nörolojik durumlarin tedavisinde faydali olabilir. Nizofenon, yavas içeri akimi ve zamana bagli potasyum disari akimini doza bagli bir sekilde azaltir. Bu bulgular, nizofenonun sinoatriyal dügüm preparasyonlarinin otomatikligi üzerinde hem içe hem de disa akimlar üzerindeki etkiler yoluyla inhibitör bir etki uyguladigini göstermektedir. Nizofenon'un subaraknoid kanamayi (SAK) takiben gecikmis iskemik nörolojik defisitlerin tedavisinde faydali olabilecegini göstermektedir. Farelerde nizofenon uygulamasinin kronik kisitlama stresinin neden oldugu bilissel bozukluklar üzerindeki etkilerini arastirildi. Yetiskin erkek fareler bes gruba randomize edildi: kontrol grubu, nizofenon kontrol grubu, kronik kisitlama stres grubu ve nizofenon tedavi gruplari (3.0 mg/kg ve , açik alan ve adim adim testler ile incelendi. Sonuçlara göre KRS grubundaki bilissel performanslarin, hipokampus ve prefrontal kortekste oksidatif parametrelerde, asetilkolinesteraz aktivitesinde ve katekolamin düzeylerinde gözle görülür degisiklikler esliginde belirgin sekilde bozuldugunu gösterdi. Bu degisiklikler nizofenon tedavisi ile tersine çevrilebilir. Dahasi, KRS grubu, nizofenon tedavi gruplarinda tersine dönen serumda daha yüksek kortikosteron seviyeleri ve daha düsük katekolamin seviyeleri gösterdi. Toplu olarak, mevcut sonuçlar, nizofenonun CRS'nin neden oldugu bilissel bozukluklari azaltma potansiyelini ortaya koydu. l- Methoxamine: Ilacin her formunu kapsar (tablet, capsül, suppozutuar, süspansiyon, Ilakon, ampul, serum, vb) Bunun yaninda temel molekül ailesi olarak benzer olan ayni etki mekanizmasi ile etkili olan kardes ilaçlarda kismen de olsa bu hastalikta etkili olabilmektedir. Patent korumasinin bu alani da kapsamasi /içermesi gerekmektedir. 2- Alprostadil: Ilacin her formunu kapsar (tablet, capsül, suppozutuar, süspansiyon, Ilakon, ampul, serum, vb) Bunun yaninda temel molekül ailesi olarak benzer olan ayni etki mekanizmasi ile etkili olan kardes ilaçlarda kismen de olsa bu hastalikta etkili olabilmektedir. Patent korumasinin bu alani da kapsamasi /içermesi gerekmektedir. 3- Nizofenone: Ilacin her formunu kapsar (tablet, capsül, suppozutuar, süspansiyon, Ilakon, ampul, serum, vb) Bunun yaninda temel molekül ailesi olarak benzer olan ayni etki mekanizmasi ile etkili olan kardes ilaçlarda kismen de olsa bu hastalikta etkili olabilmektedir. Patent korumasinin bu alani da kapsamasi /içermesi gerekmektedir. Bulusun Uygulama Biçimi Bulus; Yas ile beraber ortaya çikan KRONIK BÖBREK yetmezliginin ilaç tedavisinde kullanilmak üzere gelistirilmis kompozisyon ile ilgilidir. Tedavide kullanilacak ilacin içerisinde bulunan ürünlerin oranlari; Methoxamine (l) 2x1, Alprostadil (2) 2x1 ve Nizofenone (3) lXl dozunda ar-ge çalismalari sonucu ortaya çikmis ürün ile ilgilidir. Bu bulus: Yas ile beraber ortaya çikan KRONIK BÖBREK yetmezliginin ilaç tedavisinde kullanilmak üzere gelistirilmis bir kompozisyon ilgili olup; Methoxamine (l), Alprostadil (2) ve Nizofenone (3) kisimlarindan olusmaktadir. TR TR TR TR DESCRIPTION A COMPOSITION DEVELOPED TO BE USED IN THE MEDICAL TREATMENT OF CHRONIC RENAL FAILURE OCCURS WITH AGE This invention: It relates to a composition developed to be used in the drug treatment of CHRONIC RENAL FAILURE Occurring with age; It consists of Methoxamine, Alprostadil and Nizofenone parts. Kidney failure, also known as end-stage renal disease, is a medical condition in which the kidneys can no longer adequately filter waste products from the blood and function at less than 15% of normal levels. Renal failure is classified into acute renal failure, which develops rapidly and can resolve, and chronic renal failure, which develops slowly and can often be irreversible. Causes of acute kidney failure include low blood pressure, urinary tract obstruction, certain medications, muscle breakdown, and hemolytic uremic syndrome. State of the Art Causes of chronic renal failure include diabetes, high blood pressure, nephrotic syndrome and polycystic kidney disease. Diagnosis of acute failure is often based on a combination of factors such as decreased urine production or increased serum creatinine. The APOL1 gene has been proposed as a major genetic risk locus for a spectrum of nondiabetic renal failure in individuals of African descent, including HIV-associated nephropathy (HIVAN), primary nonmonogenic forms of focal segmental glomerulosclerosis, and hypertension-associated chronic kidney disease. Two West African variants in APOL1 have been shown to be associated with end-stage renal disease in African Americans and Hispanic Americans. Treatment of acute failure depends on the underlying cause. Treatment of chronic failure may include hemodialysis, peritoneal dialysis, or kidney transplantation. Treatment of chronic failure may include hemodialysis, peritoneal dialysis, or kidney transplantation. Hemodialysis uses a machine to filter blood outside the body. In peritoneal dialysis, specific fluid is placed in the abdominal cavity and then drained, this process is repeated several times a day. A kidney transplant involves surgically implanting a kidney from someone else and then taking immunosuppressant medication to prevent rejection. Other recommended measures against chronic disease include staying active and certain dietary changes. Depression is also common in patients with kidney failure and is associated with poor outcomes, including decreased kidney function, increased risk of hospitalization, and death. A recent PCORI-funded study in renal failure patients receiving outpatient hemodialysis found similar effectiveness between pharmacological and non-pharmacological treatments for depression. Chronic kidney failure is measured in five steps calculated using a person's GFR, or glomerular filtration rate. Stage 1 CKD is mildly reduced kidney function with few obvious symptoms. Stages 2 and 3 require increasing levels of supportive care from their medical providers to slow and treat kidney dysfunction. People with stage 4 and 5 kidney failure usually need to be prepared for active treatment to survive. Stage 5 CKD is considered a serious disease and requires some form of renal replacement therapy (dialysis) or kidney transplantation when possible. The risk of spontaneous intra-abdominal bleeding is higher in end-stage renal disease patients undergoing hemodialysis than in the general population (21.2%) and non-obstructive mesenteric ischemia (18.1%). Meanwhile, those undergoing peritoneal dialysis have a higher chance of developing peritonitis and gastrointestinal perforation. However, the rate of acute pancreatitis is no different from the general population. Treatment of acute kidney injury depends on the cause. Treatment of chronic kidney failure may include renal replacement therapy: hemodialysis, peritoneal dialysis, or kidney transplantation. Chronic kidney failure occurs in approximately 3 in 10,000 people and 1 in 1,000 people each year. While acute renal failure is usually reversible, chronic failure is usually irreversible. Disclosure of the Invention In the United States, acute kidney transplant failure affects approximately 3 in 1000 people annually. There are 395,121 people with chronic kidney failure who receive hemodialysis or peritoneal dialysis every year in China, where new chronic kidney failure is detected every year. The percentage of the Chinese population with chronic kidney disease is 10.8%. it accounted for six percent of the entire Medicare budget. Kidney disease is the ninth leading cause of death, and the United States has one of the highest mortality rates for dialysis care in the industrialized world. In England, dialysis service is run by NHS England. Approximately 23,000 patients use the service each year. It is accepted that there is no option other than kidney transplantation or hemodialysis in chronic kidney failure. The drug treatment of age-related renal failure is unknown. However, with the treatment protocol we have developed, we believe that the kidney functions of elderly patients with age-related Stage 3 or 4 kidney failure can improve and they may not need dialysis. With the treatment protocol we have developed, it will be possible to heal especially early stage Chronic Kidney Failure with drug therapy. Especially if patients newly diagnosed with Chronic Kidney Failure are treated with the treatment protocol we have developed, the patient will be able to fully recover. The implementation of the treatment protocol covers a limited period of time. The patient will be prevented from using medication throughout his life. By including patients with Chronic Kidney Failure in working life, loss of workforce in working life can be prevented and insurance treatment costs will be reduced significantly. The losses it causes to the family and the country's economy can be prevented. With the new treatment protocol we have developed, the treatment of Chronic Kidney Failure will be at the core. It is possible for patients to get rid of Chronic Kidney Failure by stopping the progression of the disease. Patients will be prevented from using medication throughout their lives. For this reason, drug-related side effects caused by continuous use of medications can be prevented. The quality of life of the patients in their working lives will be appropriate to their age, and economic losses due to overtime losses in the patients' working lives will be eliminated. There are millions of sick people whose productivity in working life decreases and their quality of daily life and freedom are limited due to Chronic Kidney Failure. Both treatment and medication costs and the stress of having to live in accordance with the daily diet continue to be a psychological burden. We can make a great contribution to the country's economy by reducing the health expenses of patients with Chronic Kidney Failure. The composition we recommend for CHRONIC RENAL FAILURE that occurs with age: It consists of Methoxamine (l), Alprostadil (2) and Nizofenone (3). The duration of use of the composition we recommend in the drug treatment of CHRONIC RENAL FAILURE, which occurs with age, can be 1 - 6 months, depending on the stage of the disease. 1. Methoxamine Methoxamine is an (11-adrenergic receptor agonist. It is an alpha adrenergic agonist used to treat hypotension. It is structurally similar to butaxamine and 2,5-DMA. Methoxamine acts as a pure alpha-1 adrenergic receptor agonist. It acts via peripheral vasoconstriction and consequently increases systemic blood pressure (both systolic and diastolic). Methoxamine has little if any direct effect on the central nervous system, causing prolonged peripheral vasoconstriction. Methoxamine is a potent sympathomimetic amine that increases diastolic blood pressure and is also indicated for the prevention and treatment of acute hypotensive state resulting from spinal anesthesia, as well as as adjunctive treatment of hypotension due to bleeding, drug reactions, surgical complications, and shock due to trauma or tumor-related brain damage. Methoxamine acts on both β-adrenergic receptors but appears to have no effect on β-adrenergic receptors. It works by increasing the power of the heart's pumping action and constricting peripheral blood vessels. 2. Alprostadil Alprostadil, also known as Prostaglandin El (PGEl), is a potent vasodilator agent. Alprostadil has numerous effects, such as vasodilation, protecting endothelial cells, and inhibiting the activation and aggregation of neutrophils and platelets. Clinical research has shown that alprostadil is effective against ischemia reperfusion injury, contrast nephropathy and diabetic nephropathy, etc. showed that it could reduce the expression of inflammatory factors such as myeloperoxidase (MPO), TNF-(x, and IL-6) in its treatment. Additionally, PGEl improved myocardial microcirculation and alleviated the apoptosis of myocardial cells. Prostaglandin El (PGEl), also known as alprostadil, is a naturally occurring enzyme used as a medicine. Prostaglandin El belongs to the vasodilator drug family. It works by relaxing the smooth muscles and opening the blood vessels until ductus arteriosus surgery can be performed. Prostaglandin El is used in healthy patients without coronary artery disease and/or genetic disorders. Alprostadil, biosynthesized in humans from dihomo-γ-linolenic acid (an omega-6 fatty acid), increased cell viability of LPS-stimulated H9c2 cells, decreased LDH (lactate dehydrase) and troponin production, and decreased IL-1ß, IL-6. It decreased the secretion of IL-17 and TNF-α. Moreover, alprostadil decreased the mRNA expression of Wnt5a, JNK, and NF-κB, and the expression of Wnt5α, NF-κB, and the p-JN K/JN K ratio in LPS-treated H9c2 cells. 3. Nizophenone Nizophenone is a neuroprotective drug that protects neurons from death following cerebral anoxia (cessation of oxygen supply to the brain). Therefore, it may be useful in the treatment of acute neurological conditions such as stroke. Nizophenone reduces slow influx and time-dependent potassium efflux in a dose-dependent manner. These findings suggest that nisofenone exerts an inhibitory effect on the automaticity of sinoatrial node preparations through effects on both inward and outward flows. It shows that nizophenone may be useful in the treatment of delayed ischemic neurological deficits following subarachnoid hemorrhage (SAH). The effects of nisophenone administration on cognitive disorders caused by chronic restraint stress in mice were investigated. Adult male mice were randomized into five groups: control group, nisophenone control group, chronic restraint stress group and nisophenone treatment groups (3.0 mg/kg and , were examined by open field and stepwise tests. The results showed that the cognitive performances in the CRS group were significantly affected by the hippocampus and prefrontal cortex. showed marked impairments accompanied by visible changes in oxidative parameters, acetylcholinesterase activity, and catecholamine levels. Moreover, the CRS group showed higher corticosterone levels and lower catecholamine levels in serum, which were reversed in the nisophenone treatment groups. The current results revealed the potential of nisofenone to reduce cognitive impairment caused by CRS. l- Methoxamine: Covers all forms of the drug (tablet, capsule, suppository, suspension, vial, ampoule, serum, etc.) Besides, the basic molecule family is similar. Sister drugs that are effective with their mechanism of action may also be partially effective in this disease. Patent protection should also cover/include this area. 2- Alprostadil: It covers all forms of the drug (tablet, capsule, suppository, suspension, vial, ampoule, serum, etc.). In addition, its sister drugs, which are similar in terms of basic molecule family and are effective with the same mechanism of action, can also be partially effective in this disease. Patent protection should also cover/include this area. 3- Nizofenone: It covers all forms of the drug (tablet, capsule, suppository, suspension, vial, ampoule, serum, etc.). In addition, its sister drugs, which are similar in terms of basic molecule family and are effective with the same mechanism of action, can also be partially effective in this disease. Patent protection should also cover/include this area. Application Form of the Invention Invention; It is related to the composition developed for use in the drug treatment of CHRONIC RENAL FAILURE, which occurs with age. The proportions of the products contained in the medicine to be used in the treatment; It is about the product that emerged as a result of R&D studies at the dosage of Methoxamine (l) 2x1, Alprostadil (2) 2x1 and Nizofenone (3) lXl. This invention relates to a composition developed for use in the drug treatment of CHRONIC RENAL FAILURE that occurs with age; It consists of Methoxamine (1), Alprostadil (2) and Nizofenone (3). TR TR TR TR
Claims (1)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR2023000874A2 true TR2023000874A2 (en) | 2023-02-21 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stroup et al. | Results of phase 3 of the CATIE schizophrenia trial | |
| Daniel et al. | Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia | |
| Leppik | Epilepsy in the elderly | |
| Ries et al. | Tricyclic antidepressant therapy for peptic ulcer disease | |
| TW200418489A (en) | Method for treating severe heart failure and medicament therefor | |
| Handler | Lithium and antihypertensive medication: a potentially dangerous interaction | |
| Ramirez et al. | Risk factors associated with xerostomia and reduced salivary flow in hypertensive patients | |
| Mackay et al. | Minoxidil in the management of intractable hypertension | |
| RU2322985C2 (en) | Using flumazenil in production of drug for treatment of cocaine abuse | |
| Feely et al. | New drugs. H2 receptor antagonists--cimetidine and ranitidine. | |
| TR2023000874A2 (en) | COMPOSITION DEVELOPED FOR USE IN THE DRUG TREATMENT OF CHRONIC RENAL FAILURE OCCURS WITH AGE. | |
| Krishnan et al. | Captopril in the treatment of cardiovascular manifestations of Indian red scorpion (Mesobuthus tamulus concanesis Pocock) envenomation | |
| Marsh | Clinical features of malaria | |
| Schou | The recognition and management of lithium intoxication | |
| Dunn et al. | Mental disturbance in the ill old person. | |
| AU2001279275A1 (en) | Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies | |
| Perry et al. | Survival of treated hypertensive patients | |
| US20040176387A1 (en) | Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies | |
| Turedi et al. | First time, low dose citalopram use-related serotonin syndrome | |
| de Mendonca et al. | Renovascular status after renal surgery for hypertension | |
| Kavanagh | Antihypertensive drugs | |
| CN113730585A (en) | Small-dose combined medicine composition for treating refractory hypertension | |
| Shinde et al. | To Study the Efficacy of Jatamansi Phanta in Hypertension | |
| Yu et al. | Systematic Nonpain Symptom Assessment and Management | |
| Indushree | Comparison of Frequency of Orthostatic Hypotension in Hypertensive Dialysis Patients on a Combination of Antihypertensive Therapy with and Without Prazosin |